<DOC>
	<DOCNO>NCT02384512</DOCNO>
	<brief_summary>End-of-dose fluctuation e. g. wearing-off define recurrence motor non-motor Parkinson 's Disease ( PD ) symptoms precedes schedule dose improves next dose anti-parkinsonian medication . Azilect® approve recommended therapy wearing-off-/End-of-dose fluctuation improve motor fluctuation significantly combination therapy L-dopa parkinsonian medication .</brief_summary>
	<brief_title>Azilect® In Wearing-Off ( AIWO )</brief_title>
	<detailed_description>The aim non-interventional study document efficacy tolerability rasagiline combination therapy patient wearing-off-/End-of-dose fluctuation effect rasagiline individual wearing-off symptom , recognize wearing-off questionnaire 32 ( WOQ-32 ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Inclusion : idiopathic Parkinson 's disease base UK Brain Bank criterion , Wearingoff / endofdose akinesia least 18 year old , write consent participate study . Exclusion : contraindication accord SmPC Azilect® , treatment Azilect® past 3 month / suffer relevant cognitive impairment therefore neither understand patient information , give consent participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>akinesia</keyword>
	<keyword>Azilect®</keyword>
	<keyword>Rasagiline</keyword>
	<keyword>Combination therapy L-dopa</keyword>
	<keyword>Wearing-off Questionnaire-32</keyword>
	<keyword>Quality life</keyword>
	<keyword>Daily practice</keyword>
</DOC>